Na mbido Maachị, National Medical Products Administration kwadoro Jaypirca® (pirtobrutinib) maka ọgwụgwọ nke ndị toro eto nwere ọrịa leukemia lymphocytic na-adịghị ala ala (CLL) ma ọ bụ obere lymphoma lymphocytic (SLL) bụ ndị natara ma ọ dịkarịa ala otu ọgwụgwọ sistemu tupu oge eruo, gụnyere ihe mgbochi Bruton's tyrosine kinase (BTK).
Pirtobrutinib bụ ọgwụ mgbochi kinase nke a na-ahọrọ nke ukwuu nke na-eji usoro njikọ ọhụrụ na-abụghị covalent iji gbasaa uru nke ilekwasị anya na ụzọ BTK na ndị ọrịa CLL/SLL ejiri ọgwụ mgbochi BTK covalent gwọọ (ibrutinib, acalabrutinib, ma ọ bụ zanubrutinib). Pirtobrutinib natara nkwado site na US FDA na Jenụwarị 2023 dị ka ọgwụ mgbochi BTK na-abụghị covalent (reversible). Na Ọktoba 2024, a kwadoro pirtobrutinib na China dị ka ọgwụ ọgwụgwọ maka ọgwụgwọ ndị okenye nwere ọrịa lymphoma mantle cell relapsed ma ọ bụ refractory (MCL) bụ ndị natara ọgwụgwọ sistemụ abụọ mbụ, gụnyere ọgwụ mgbochi Bruton's tyrosine kinase (BTK).
Nkwenye nke ihe ngosi ọhụrụ a dabere na nsonaazụ sitere na ọmụmụ BRUIN CLL 321 nke mba ụwa, nke nwere ọtụtụ etiti, nke enweghị usoro. BRUIN CLL 321 bụ nnwale nke mbụ nke usoro nke atọ emere n'ụwa n'ime ndị ọrịa nwere CLL/SLL bụ ndị ejiri ihe mgbochi BTK covalent (cBTKi) gwọọ na mbụ. Ọmụmụ ihe ahụ debara aha ndị ọrịa 238 ma nyochaa irè na nchekwa nke pirtobrutinib monotherapy megide nhọrọ onye nyocha nke IdelaR (idelalisib plus rituximab) ma ọ bụ BR (bendamustine plus rituximab). Nsonaazụ ahụ gosiri na pirtobrutinib nwere ndụ ogologo oge dị ogologo (PFS) ma e jiri ya tụnyere usoro nhọrọ onye nyocha (ọnwa 14.0 vs ọnwa 8.7; oke ihe egwu [HR] = 0.54). Tinyere nke ahụ, ọnụego nkwụsị n'ihi ihe ọjọọ metụtara ọgwụgwọ dị ala na pirtobrutinib (5.2% vs 21.1%), nke na-akwado arụmọrụ ya na uru ndidi ya na ndị ọrịa ejiri covalent BTK inhibitor gwọọ na mbụ.
Kpọtụrụ Anyị Ka Ị Malite Njem Olileanya Gị
Ụlọ Ọgwụ Ọrịa Oncology nke Mba Nile nke Beijing South Region raara onwe ya nye inye ndị ọrịa zuru ụwa ọnụ ohere ịnweta ọgwụgwọ kansa kachasị elu. Ọ bụrụ na gị ma ọ bụ onye ezinụlọ gị na-eche ihu na ọrịa kansa ma nwee mmeghachi omume na-ezighi ezi na ọgwụgwọ ọdịnala, ndị otu Ọrụ Ndị Ọrịa Mba Nile anyị dị njikere inye gị ozi zuru ezu na atụmatụ ọgwụgwọ ahaziri iche.
Biko kpọtụrụ anyị site na ọwa ndị a ka ịmatakwu gbasara nhọrọ ọgwụgwọ ọrịa kansa:
- Ekwentị: 400-880-3716
- WeChat: 17801183037
- Email: 100085_010@163.com or myimmnet@163.com (Emails are welcome, and we will respond promptly)
Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region na-atụ anya iso gị rụkọọ ọrụ n'ọgụ megide ọrịa kansa. N'agbanyeghị ebe ị nọ n'ụwa, anyị na-agba mbọ inye gị nkwado ahụike kachasị mma na nlekọta ọmịiko.
Take the first step towards overcoming your illness. Call us at 400-880-3716 or contact us via WeChat at 17801183037 today. You can also email us at 100085_010@163.com or myimmnet@163.com to schedule a one-on-one consultation with our team of experts.
Oge ozi: Maachị-12-2026